

RETENSION PHARMACEUTICALS, INC.

Reported by
B GROUP, INC.

FORM 3

(Initial Statement of Beneficial Ownership)

Filed 10/16/26 for the Period Ending 10/13/26

Address	C/O REDUX THERAPEUTICS, LLC 902 TURKEY RUN ROAD MCLEAN, VA, 22101
Telephone	(703) 624-2024
CIK	0002002988
Symbol	RTSN
SIC Code	2834 - Pharmaceutical Preparations
Fiscal Year	12/31

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the
Investment Company Act of 1940

1. Name and Address of Reporting Person * B Group, Inc.	2. Date of Event Requiring Statement (MM/DD/YYYY) 10/13/2026	3. Issuer Name and Ticker or Trading Symbol Retension Pharmaceuticals, Inc. [RTSN]
(Last) (First) (Middle) 2900 MCKINNON STREET SUITE 1101	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ Director ☒ 10% Owner ____ Officer (give title below) _____ Other (specify below) _____	
(Street) DALLAS TEXAS 75201	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) ☒ Form filed by One Reporting Person ☐ Form filed by More than One Reporting Person
(City) (State) (Zip/Postal Code) UNITED STATES		
(Country)		

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	833,333	I	See Note 1 (1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Explanation of Responses:

(1) The reporting persons are The B Group, Inc. ("B Group"), B Group Capital LLC (the "Fund") and Branden B. Muhl. B Group is the investment adviser of the Fund. Mr. Muhl is the manager and controlling owner of the Fund and B Group, respectively. B Group is filing this Form 3 for itself, the Fund and Mr. Muhl. The securities are held directly by the Fund. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 3d-5(b) under the Securities Exchange Act of 1934, as amended. B Group may be deemed to indirectly beneficially own the securities as the investment adviser to the Fund. Mr. Muhl may be deemed to indirectly beneficially own securities as the manager of the Fund and control person of B Group. The reporting persons disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
B Group, Inc. 2900 MCKINNON STREET SUITE 1101 DALLAS TEXAS 75201 UNITED STATES		X		

Signatures

/s/ Branden B. Muhl, Chief Executive Officer

10/16/2026

Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

* Form 3: SEC 1473 (03-26).